Ritz Club & Spa
Welcome to the second iteration of Vogue's global spa guide, an index of the 100 best spas in the world, built from the expertise of our global editors and trusted contributors. There is a lot to choose from in the world of wellness, and no matter how far you're planning to travel—from a subway ride to a transatlantic flight—we want to make sure it's worth the journey. Whatever your path, let us be your guide.
Why go here?
The Ritz Paris needs little introduction: It's one of the most iconic hotels in the world, with everyone from Coco Chanel to Marcel Proust to Kim Kardashian having walked through the famous revolving doors on the Place Vendôme and spent the night in one of its silk-canopied beds. (Unsurprisingly, perhaps, the Ritz has also served as the backdrop for multiple Vogue shoots over the decades.) But the Ritz Club & Spa is its hidden secret: Tucked away on the rear side of the building, it's a subterranean wellness oasis that blends the hotel's, well, ritzy interior design with the latest in wellness and fitness.
Photo: Jerome Galland / Courtesy of Sommerro Vestkantbadet
What's the vibe?
If you're arriving for the day, the Ritz Club & Spa has a dedicated entrance on Rue Cambon, where you'll descend a staircase to be greeted by a throng of staff standing in tweed jackets behind a glossy white spaceship of a reception desk. But if you're staying as a guest, you get the real luxury of padding down in the robes and slippers through a (somewhat labyrinthine) network of underground corridors.
After a quick pit stop in the changing rooms, you'll step out into the spa's dramatic crown jewel: the expansive central pool area, with its sweeping double staircase, murals of Italianate gardens on the walls, and a ceiling frescoed with a heavenly blue sky gently streaked by clouds. The treatment rooms are things of beauty too: oversized watercolor-style flowers adorn the walls, while floral light fixtures on the ceilings fade to a soothing twinkle as your treatment begins. Once you're happily ensconced in your cabin, you'd never guess you were in the beating heart of one of the world's most hectic cities.
Photo: Jerome Galland / Courtesy of Sommerro Vestkantbadet
The history?
There are few hotels with quite as illustrious a history as the Ritz Paris: Established in 1898 by the legendary hotelier César Ritz, it was the first hotel in the world to feature electricity on every floor and private bathrooms in every room. Things have come along since then, of course: The Ritz Club & Spa opened in the 1980s and was equally game-changing in the kinds of treatments it offered, bringing collagen-infused products and other cutting-edge techniques to Paris—and quickly becoming a favorite of the city's glitterati. (If my visit was anything to go by, the clientele here still has plenty of glitter.)
What should you try?
The Ritz is one of the very few Paris hotels to work with Biologique Recherche, the French beauty brand notorious for their strict requirements around collaborations—clearly, the team here is one they trust. (And now, the many fashion editors who make their seasonal pilgrimage to Biologique's palatial 'ambassade' on the Champs-Élysées for a facial need travel no further than the 1st arrondissement.)
On my visit earlier this year, I went for the 90-minute 'ultimate hydration' facial—just the ticket after a long-haul flight—and was ushered into one of those gorgeously decorated cabins. Beginning with a classic cleanse and tone, I was then treated to a customized mask that had been adjusted to match my skin type with the specific goal of helping to drench and plump my parched visage. Emerging back into the relaxation area with a cup of freshly brewed herbal tea and catching a glimpse in one of the gilded mirrors, I was astonished to discover that my jet lag-induced eye bags had disappeared. Call it magic, or call it Biologique.
Photo: Jerome Galland / Courtesy of Sommerro Vestkantbadet
What else do we need to know?
This being Paris—and the fact that many guests are likely in town for a red carpet event of some sort—the spa comes equipped with a truly opulent hairdressers and nail bar, the latter in collaboration with the Parisian polish brand Kure Bazaar, who created a unique shade of 'Ritzy' red especially for the hotel. And if you're a gym fanatic, the mirrored fitness studio is unusually expansive for a central Paris hotel, offering cutting-edge Matrix Fitness machines and over 40 classes a week. (Including dance sessions, should you be feeling particularly inspired by a visit to the ballet at the Opéra Garnier during your Parisian sojourn.)
Who can go?
Hotel guests can use the amenities free of charge without booking. Day access is also granted to those booking treatments over a certain price threshold, and locals can join the Ritz Club & Spa for the facilities and classes for a monthly fee.
Photo: Jerome Galland / Courtesy of Sommerro Vestkantbadet
Booking details for Ritz Club & Spa
Address: 17 Pl. Vendôme, 75001 Paris, France
Read more from Vogue's Global Spa Guide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
33 minutes ago
- Forbes
The French Open Night Session Needs To Create Wiggle Room For Women
PARIS, FRANCE - MAY 29: Iga Swiatek of Poland (L) shakes hands with Naomi Osaka of Japan after her ... More victory in the Women's Singles second round match during Day Four of the 2024 French Open at Roland Garros on May 29, 2024 in Paris, France. (Photo by) After beating Tommy Paul in 94 minutes during the Tuesday night session at the French Open, Carlos Alcaraz apologized to the crowd. 'I have to say, I know you wanted to watch more tennis. I have to say sorry about it. I had to do my work but, once again, it's great to play in front of all of you,' the defending champion said as he made it through to the semifinals. On Wednesday, the two women's quarterfinal matches – which were won in straight sets by Iga Swiatek and Aryna Sablenka – both lasted longer than Alcaraz's demolition job on the American. On Sunday, Swiatek played former Wimbledon champion Elena Rybakina in a two-and-a-half-hour epic, a match that started in a virtually empty Phillippe-Chatrier Court. Two Slam winners in a quiet amphitheater felt wrong. They didn't need to play an incredible encounter to justify the slot. World No.1 Sabalenka has spoken directly on how women's tennis should have an equal billing with the men's side. "There were a lot of great battles that would be cool to see as a night session. More people in the stands watching these incredible battles. Just to show our self to more people. I definitely agree that we deserve to be put on a bigger stage, better timing, more people watching,' Sabalenka said after her victory over Qinwen Zheng. The storyline was strong. Sabalenka lost to her Chinese rival for the first time at the Italian Open. This was her fight to get her major rights back. Clearly, the narrative wasn't strong enough to reach out to the peak hours. Four-time French Open champion Swiatek, who will face Sabalenka in a blockbuster semifinal on Thursday, agreed in more low-key style. Ons Jabeur pushed back more forcefully. 'Of course, they watch men more because you show men more. Everything goes together,' said the two-time Wimbledon runner-up. The debate about the evening sessions being the domain of the men was validated to some degree by tournament director Amelie Mauresmo. 'Since men's tennis is played at the best-of-five sets, three sets will be played at a minimum. It's complicated for us to do otherwise." 'It's complicated' is a diplomatic way of suggesting that the fear of a woman's match to deliver, to not go deep into the night will always dictate the schedule. In a one-on-one contest, the men will always prevail right here, right now in the French Open. Novak Djokovic's 41-shot rally to fend off Alexander Zverev just before midnight made good visuals and got Mauresmo off the hook to some extent. The tournament needed a near midnight finish after Sinner blasted Andrey Rublev away and Alcaraz's quick kill of Paul. One look at last year's epic second-round clash between Swiatek and Naomi Osaka in Paris is to see what is possible. 'Swiatek v Osaka is a brilliant watch. '[The] WTA need to do more to capitalise on these match ups!,' said Mauresmo's former client Andy Murray, but the match was played in front of a half-empty court. Dimple Thakkar is the CEO of Fifteen Thirty Forty, a next-gen tennis brand. "Swiatek versus is not a risk. That's a blockbuster. Fans don't want longer matches. They want meaningful ones. It's about fear—of evolution, of disruption, of rethinking power dynamics. Sidelining women's tennis in prime time isn't just outdated. It's leaving relevance—and revenue—on the court," Thakkar told me. Only four women's matches have taken center stage for the closing hours of play since night sessions were introduced at Roland Garros in 2021. The Australian Open and U.S. Open have two matches that can go into the early hours of the morning. Technically, this offers value for money but sessions that end at 3 am naturally lose fans because of overtime and also impact player welfare. Spectators attend the night session of the men's singles match between Italy's Jannik Sinner and ... More France's Richard Gasquet on Court Philippe-Chatrier on day four of the French Open tennis tournament at the Roland Garros Complex in Paris on May 29, 2024. (Photo by Dimitar DILKOFF / AFP) (Photo by DIMITAR DILKOFF/AFP via Getty Images) Sabalenka herself wasn't best pleased when she was made to start her third-round match against Ekaterina Alexandrova in the early hours of the morning at Flushing Meadows in August. 'I was like 'no way.. I'm gonna start at midnight'. And that's actually what happened. That was tricky,' said the Belarusian at the time. This was after Novak Djokovic get knocked out by Alexei Popyrin in front of a 24,000-capacity crowd on Arthur Ashe. 'WNBA viewership is up 300%. Women's NCAA games are shattering TV records. The market has spoken—loudly. And yet, somehow, women's tennis still gets benched at night,' Thakkar told me. The gentlemen's club still hold the cards.
Medscape
an hour ago
- Medscape
Can Cold Exposure Alter Energy Dynamics in Obesity?
In individuals with obesity, 90 minutes of cold exposure increases energy expenditure by 18% but also raises energy intake and causes significant discomfort. METHODOLOGY: There is a growing interest in using cold exposure as a potential weight loss strategy via its ability to increase energy expenditure and create a negative energy balance. Researchers assessed the effects of moderate cold exposure on energy expenditure, energy intake, and appetite regulation in 29 women (mean age, 27.6 years) and 18 men (mean age, 31.5 years) with obesity who engaged in fewer than two 30-minute continuous exercise sessions per week. Participants underwent two 90-minute sessions — one at 10 °C and one at ambient temperature — in a random order, separated by a minimum 2-week washout. A single dose of cold exposure involved wearing a liquid-conditioned suit with circulating diluted antifreeze. Researchers measured thermal comfort/sensation, subjective appetite (via visual analog scales), energy expenditure (via indirect calorimetry), and energy intake with a validated food menu that calculated total food consumed; blood samples were analyzed for appetite-related peptides. TAKEAWAY: Compared with exposure to ambient temperature, cold exposure over 90 minutes led to: An 18% increase in energy expenditure primarily due to increased glucose oxidation ( P < .001) Significantly reduced average skin temperature (33.0 °C vs 24.5 °C, respectively; P < .001) and decreased thermal comfort Increased energy intake during lunch following intervention ( P = .008), especially from carbohydrate and protein consumption ( P = .007 and P = .014, respectively), although intake decreased for the rest of the day ( P = .049) Decreased leptin level ( P = .004) and increased level of total glucagon-like peptide 1 ( P = .003) No significant changes were observed in subjective appetite, such as hunger, desire to eat, and fullness. IN PRACTICE: 'The negligeable impact on [energy expenditure], as well as the overall absence of effects on [energy intake], seem to make [cold exposure] an unlikely candidate for improved body weight control in individuals with obesity,' the authors wrote. SOURCE: The study was led by Kurt McInnis, University of Ottawa in Ottawa, Ontario, Canada. It was published online in International Journal of Obesity . LIMITATIONS: Energy expenditure was measured in a postprandial state, potentially masking the true effects compared with fasting conditions. The study used only a single dose of cold exposure, so the effects of repeated exposure remain unknown. Core body temperature was not measured. DISCLOSURES: This study was supported by a grant from the Canadian Institute of Health Research. One author disclosed receiving support from Bausch Health Canada. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. Credit Lead image: Intoit | Dreamstime Medscape Medical News © 2025 WebMD, LLC Cite this: Can Cold Exposure Alter Energy Dynamics in Obesity? - Medscape - June 05, 2025.
Medscape
2 hours ago
- Medscape
New Hyperkalemia Risk Model for CKD and Diabetes
A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications like finerenone. However, researchers caution that further validation is needed. The model is based on pooled data from two phase 3 trials of finerenone: FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) and FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease). The combined dataset, known as FIDELITY, includes 6355 patients in the placebo groups. Researchers used this dataset to develop the risk score, identifying seven factors independently associated with the primary outcome of new onset of hyperkalemia (incident serum potassium level > 5.5 mmol/L): Serum potassium > 4.5 mmol/L Prior history of hyperkalemia No use of sodium-glucose co-transporter 2 inhibitor Urine albumin-to-creatinine ratio > 1000 mg/g Hemoglobin < 12 g/dL No use of thiazide-type diuretics Estimated glomerular filtration rate < 45 mL/min/1.73 m2 The model was subsequently validated using data from the finerenone groups in FIDELITY. In their paper, published online in the European Heart Journal , João Pedro Ferreira, MD, PhD, of the Cardiovascular Research and Development Center at the University of Porto, Porto, Portugal, and coauthors noted that the model could be used to reduce the risk for hyperkalemia among high-risk patients receiving finerenone. 'This could include tailoring of individualized treatment and follow-up strategies (eg, frequency of visits and serum potassium assessments, and use of potassium binders), thus optimizing patient management and potentially improving outcomes,' they noted. Welcome Results, Validation Required CKD, which affects more than 800 million people worldwide, is a common complication of diabetes. An estimated 15%-40% of people with CKD in the setting of diabetes may have hyperkalemia, noted Bernard G. Jaar, MD, MPH, clinical director for Nephrology at Johns Hopkins School of Medicine, Baltimore, who was not involved in the study. In an email exchange with Medscape Medical News , Jaar described the study as 'welcome and much needed.' He noted that hyperkalemia poses a challenge for clinicians, as many medications required for optimal care in CKD — including renin-angiotensin-aldosterone system (RAAS) blockade agents and finerenone — can raise serum potassium. 'This is a true barrier to care,' Jaar wrote. 'Clinicians are worried about the potential complications associated with hyperkalemia, such as arrhythmias and even death.' Jaar noted that the FIDELITY analysis has several strengths, including its large sample size of patients with varying stages of CKD and degrees of proteinuria, and a risk score model that incorporated readily available clinical variables. He added that it reports a stepwise increase in hyperkalemia risk across risk score tertiles in both placebo and finerenone groups, even though all patients were already on a maximally tolerated RAAS blockade agent. However, he questioned the study's generalizability, given that it excluded patients if their serum potassium was > 4.8 mmol/L. 'This risk model in predicting hyperkalemia needs to be validated in other populations where diet may be different,' Jaar wrote. 'Also, this needs to be validated in at-risk populations during real-life experience and not only in patients enrolled in clinical trials, who are typically highly motivated and selected.' Future Applications Rajiv Agarwal, MD, MS, professor emeritus of medicine at Indiana University and a lead researcher in the finerenone clinical studies, echoed the need for further validation of this tool. Although not involved with the development of the risk model, Agarwal was an author on key publications from the FIGARO-DKD, FIDELIO-DKD, and FIDELITY studies. Agarwal suggested that this model's approach could be applied to other therapies, including aldosterone synthase inhibitors in a similar population with CKD. He also noted the importance of incorporating validated risk models for hyperkalemia into electronic medical records or apps, particularly in countries with limited access to care, like China and India. This would allow more nuanced approaches for following up patients taking drugs with established hyperkalemia risk. 'If the patient cannot come after a month, can I make a clinical judgment and say, 'Okay, if you came back after 3 months, your risk of hyperkalemia is low enough that I'm willing to take that risk,'' he said. 'Or if the risk of hyperkalemia is high, you can tell the patient who can't come back in 30 days, 'I don't think I want to prescribe this drug for you'.' The work on the risk model was supported by Bayer, which also funded the FIDELIO-DKD and FIGARO-DKD studies and pooled analysis. The study's authors included Bayer employees. Other financial relationships of the authors included research support, consulting and other fees from companies including: Abbott Vascular, Amgen, Astellas, AstraZeneca, Bayer, BioVentrix, Boehringer Ingelheim, Brahms, Brainstorm Medical, Cardiac Dimensions, Cardior, Cereno Scientific, CSL Vifor, CVRx, Edwards, Eli Lilly, G3 Pharmaceuticals, Gilead, GSK, Impulse Dynamics, Janssen, KBP Biosciences, Mundipharma, Novartis, Novo Nordisk, Occlutech, PhaseBio, Proton Intel, Respicardia, Sanofi, Sarfez, scPharmaceuticals, Servier, SQ Innovation, Tricida, Vectorious, Vifor International, and V-Wave. Agarwal had received support from Bayer. He also had received consulting fees and other support from Boehringer Ingelheim, Novartis, Akebia, Intercept Pharma, Alnylam, and Vertex. Jaar reported no relevant financial disclosures.
